Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver
disease in the Western world, probably due to the growing prevalence of obesity, metabolic …

Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of
chronic liver disease in children and adolescents. Over the past 5 years, developments have …

Several animal studies have emphasized the role of gut microbiota in nonalcoholic fatty liver
disease (NAFLD). However, data about gut dysbiosis in human NAFLD remain scarce in the …

Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation
of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are …

Prediction of hepatocellular carcinoma (HCC) risk is an urgent unmet need in patients with
nonalcoholic fatty liver disease (NAFLD). In cohorts of 409 patients with NAFLD from …

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction in
the Western world and is increasing owing to its close association with obesity and insulin …